Literature DB >> 2470735

Affinity purification of active plasminogen activator inhibitor-1 (PAI-1) using immobilized anhydrourokinase. Demonstration of the binding, stabilization, and activation of PAI-1 by vitronectin.

T C Wun1, M O Palmier, N R Siegel, C E Smith.   

Abstract

Human Hep G2 hepatoma and HT 1080 fibrosarcoma cells were cultured in large scale under conditions which allowed enhanced secretion of plasminogen activator inhibitor-1 (PAI-1). A modified urokinase was obtained by reacting urokinase with phenylmethylsulfonyl fluoride followed by alkali treatment. The resulting product, called anhydrourokinase, was found to reversibly bind the PAI-1 when immobilized on cyanogen bromide-activated Sepharose 4B beads. Using this affinity absorbent, we have purified PAI-1 from the cell-conditioned media. A number of differences have been observed during Hep G2 and HT 1080 PAI purification. 1) The PAI activity in Hep G2 medium concentrate is more stable, and the concentrate depleted of active PAI-1 showed spontaneous regeneration of PAI-1 activity. In contrast, the PAI activity in HT 1080 medium concentrate declines rapidly on standing. 2) Hep G2 PAI-1 invariably copurified with an adhesive protein, vitronectin or its NH2-terminal fragment, while pure HT 1080 PAI-1 alone was obtained by affinity purification on anhydrourokinase-Sepharose 4B. 3) Based on specific activity measurement and complex formation analysis using a sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis technique, the purified Hep G2 PAI-1 appears completely active while the HT 1080 PAI-1 is only one-fourth as active. SDS was found to exert dual effects on purified PAI-1s. SDS treatment partially inactivated a fully active Hep G2 PAI-1 and a moderately active HT 1080 PAI-1 but partially activated an HT 1080 PAI-1 whose activity had previously been allowed to decay to a very low level. Purified vitronectin was found to enhance and stabilize the PAI-1 activity of the partially active HT 1080 PAI-1. It is concluded that fully active PAI-1 in association with vitronectin can be isolated by anhydrourokinase-Sepharose 4B chromatography and that vitronectin is a binding protein for PAI-1 which activates and stabilizes PAI-1.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2470735

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease.

Authors:  Jesús M López-Guisa; Allen C Rassa; Xiaohe Cai; Sarah J Collins; Allison A Eddy
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-26

2.  Affinity-based separations and purifications. Patents and literature.

Authors:  J S Dordick
Journal:  Appl Biochem Biotechnol       Date:  1991-01       Impact factor: 2.926

Review 3.  Evidence for an extra-cellular function for protein kinase A.

Authors:  S Shaltiel; I Schvartz; B Korc-Grodzicki; T Kreizman
Journal:  Mol Cell Biochem       Date:  1993-11       Impact factor: 3.396

4.  Activation of blood coagulation and fibrinolysis in vibration syndrome.

Authors:  R Shunto; A Shirakami; A Ohara; N Toibana; S Saito
Journal:  Int Arch Occup Environ Health       Date:  1991       Impact factor: 3.015

5.  The c-myc-regulated gene mrl encodes plasminogen activator inhibitor 1.

Authors:  G C Prendergast; L E Diamond; D Dahl; M D Cole
Journal:  Mol Cell Biol       Date:  1990-03       Impact factor: 4.272

6.  Validation of the vitronectin knockout mouse as a model for studying myocardial infarction: Vitronectin appears to influence left ventricular remodelling following myocardial infarction.

Authors:  Gordon E Pate; Hubert P Walinski; Lubos Bohunek; Thomas J Podor
Journal:  Exp Clin Cardiol       Date:  2013

7.  The expression and localization of urokinase-type plasminogen activator and its type 1 inhibitor are regulated by retinoic acid and fibroblast growth factor in human teratocarcinoma cells.

Authors:  J Tienari; T Alanko; E Lehtonen; O Saksela
Journal:  Cell Regul       Date:  1991-04

8.  Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain.

Authors:  Christine R Schar; Jan K Jensen; Anni Christensen; Grant E Blouse; Peter A Andreasen; Cynthia B Peterson
Journal:  J Biol Chem       Date:  2008-07-24       Impact factor: 5.157

9.  Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1.

Authors:  M V Cubellis; T C Wun; F Blasi
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

10.  Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1.

Authors:  Jennifer C Carter; Frank C Church
Journal:  PPAR Res       Date:  2009-08-06       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.